# NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

> **NCT04550663** · PHASE1 · UNKNOWN · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 10 (estimated)

## Conditions studied

- Solid Tumor
- Hepatocellular Carcinoma
- Colorectal Cancer
- Glioma

## Interventions

- **DRUG:** KD-025 CAR-T cells

## Key facts

- **NCT ID:** NCT04550663
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-25
- **Primary completion:** 2022-09-25
- **Final completion:** 2023-03-25
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04550663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04550663, "NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04550663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*